

POSFREA™
(palonosetron) Injection

BILLING AND CODING GUIDE

If you have additional billing and coding questions, please call your Field Reimbursement Manager or AVYXASSIST™ at 866-939-8927. Our Patient Access Specialists are available to assist Monday through Friday, 8 AM to 8 PM ET.

Please see Important Safety Information on pages 3 and 13 and full [Prescribing Information](#) for POSFREA.™



TABLE OF CONTENTS

Indications and Important Safety Information	3,13
POSFREA™ Ordering Information	4
AVYXASSIST™ Patient Support Program	5
Billing and Coding Information	6-8
NDCs	6
HCPCS Code	6
J-Code Billing Unit Conversion	6
CPT Drug Administration Codes	7
ICD Diagnosis Codes	7
ICD Diagnosis Code by Indication	8
Sample Claim Form CMS-1450 (UB-04)	9-10
Sample Claim Form CMS-1500	11-12
Important Safety Information (Continued)	13
Notes	14

The contents herein provide general coverage, coding, and payment information about POSFREA.™ The information within this guide was obtained from third-party sources and is made available for reference only. It is not exhaustive, is subject to change, and does not constitute billing, coding, or legal advice. Healthcare professionals are responsible for determining which code(s), charge(s), or modifier(s), if any, appropriately reflect a service or diagnosis. It is the healthcare professional's responsibility to determine medical necessity and provide adequate documentation. AVYXA™ does not guarantee coverage or payment. Payment and coverage vary by payer. Questions about coding, coverage, and payment may be directed to the applicable third-party payer, reimbursement specialist, and/or legal counsel.

CMS: Centers for Medicare & Medicaid Services; CPT: Current Procedural Terminology; HCPCS: Healthcare Common Procedure Coding System; ICD: International Classification of Diseases; NDC: National Drug Code

**Please see Important Safety Information on pages 3 and 13
and full [Prescribing Information](#) for POSFREA.™**

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

POSFREA™ is indicated in adults for prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
- acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC).
- postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.

As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, POSFREA is recommended even where the incidence of postoperative nausea and/or vomiting is low.

POSFREA is indicated in pediatric patients 1 month to less than 17 years of age for prevention of:

- acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

POSFREA is contraindicated in patients known to have hypersensitivity to palonosetron or any of its components.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported with administration of palonosetron. These reactions occurred in patients with or without known hypersensitivity to other 5-HT₃ receptor antagonists. If hypersensitivity reactions occur, discontinue POSFREA and initiate appropriate medical treatment. Do not reinitiate POSFREA in patients who have previously experienced symptoms of hypersensitivity.

Serotonin Syndrome

The development of serotonin syndrome has been reported with 5-HT₃ receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-HT₃ receptor antagonist alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT₃ receptor antagonist use occurred in a post-anesthesia care unit or an infusion center.

Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Please see Important Safety Information on pages 3 and 13 and full [Prescribing Information](#) for POSFREA.™

POSFREA™

(palonosetron) Injection

Ordering Information

To order POSFREA™ (palonosetron) Injection, please contact one of these authorized specialty distributors and use the appropriate order #:



0.25 mg/5 mL (0.05 mg/mL)
NDC: 83831-0105-01

Institutions/Hospitals	0.25 mg/5 mL (0.05 mg/mL)
Cardinal Health Specialty	5945779
CENCORA - ASD Healthcare	10292116
Physician Offices	0.25 mg/5 mL (0.05 mg/mL)
Cardinal Health Specialty	5945779
Oncology Supply	10292154
McKesson Specialty Health	5018368

UNIQUE
J-CODE

J2468

Highlights¹

- Free from disodium edetate (EDTA)
- Free from sodium citrate
- Not made with natural rubber
- Unique J-Code: J2468

Please see Important Safety Information on pages 3 and 13 and full [Prescribing Information](#) for POSFREA.™



Simplifying Patient Access, Providing Comprehensive Support.

AVYXASSIST™ can offer support to qualifying patients in need. The program provides the following services*

- ✓ Benefit verification
- ✓ Prior authorization requirements
- ✓ Appeals process information
- ✓ Referrals to 501(c)(3) foundations when applicable
- ✓ Free product assistance (uninsured or underinsured), bridge supply (coverage delays)
- ✓ Product replacement
- ✓ Copay assistance

COPAY ASSISTANCE PROGRAM

Eligible patients may pay as little as **\$0** per dose*

TO ENROLL, PLEASE CHOOSE ONE OF THE FOLLOWING OPTIONS



Phone

866-939-8927
Monday through Friday
8 AM to 8 PM ET

CALL NOW

OR



Online

Click on the link below
to begin your online
enrollment

ENROLL NOW

OR



Fax

Download, print and fax
the completed enrollment
form to 833-852-3420

DOWNLOAD NOW

*For eligibility requirements, please contact a Patient Access Specialist. Terms and conditions apply.

Please see Important Safety Information on pages 3 and 13
and full [Prescribing Information](#) for POSFREA.™

Billing and Coding Information

The information provided is for informational purposes only and represents no statement, promise, or guarantee by AVYXA™ concerning reimbursement, payment, or charges. The information provided is not intended to increase or maximize reimbursement by any payer. Healthcare professionals are responsible for selecting appropriate codes used to file a claim. Codes should be based on the patient's diagnosis and the items and services furnished by the healthcare professional. All codes should be verified between the healthcare professional and the payer. AVYXA™ does not recommend the use of any particular diagnosis code in any billing situation for POSFREA™ (palonosetron) Injection. The below codes are for reference only; coding as submitted is the sole responsibility of the prescribing physician.

NDCs

POSFREA™ NDC ¹	Strength	Package
83831-0105-01	0.25 mg/5 mL (0.05 mg/mL)	Single-dose vial, carton of 1

HCPCS Code²

HCPCS Level II codes are used to identify most drugs and biologics that are given in the office.

POSFREA™ Unique J-Code	Description
J2468	Injection, palonosetron hydrochloride (AVYXA™), not therapeutically equivalent to J2469, 25 micrograms

J-Code Billing Unit Conversion³

25 micrograms of POSFREA™ equals one (1) billing unit. When billing for quantities greater than 25 micrograms, indicate the total amount used as a multiple of billing units on the claim form. Examples:

Vial Strength	Billing Units
One (1) Vial (5 mL) or 0.25 mg	10 billing units

NOTE: There are a few HCPCS codes for palonosetron but there is only one HCPCS code for POSFREA™ (J2468), so please make sure the HCPCS code matches the product purchased and administered.

CPT Drug Administration Codes^{3,4}

CPT codes are used to bill drug administration services provided in the physician's office and other outpatient settings.

CPT Code	Description
96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug
96375*	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)

CPT codes, descriptions, and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/ HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

POSFREA™ is packaged as a single-dose vial¹. Medicare will pay for drug waste on single-use items that are medically necessary and appropriately documented in the patient's medical record. Medicare requires discarded drugs to be reported with the JW modifier on a separate line; if there is no waste, POSFREA™ must be billed on one line with modifier -JZ. Medicare requires this; please ascertain if other payers require JZ and JW modifiers.⁵

*The recommended dosage of POSFREA™ for chemotherapy-induced nausea and vomiting is a 0.25 mg dose over 30 seconds, starting the dosing approximately 30 minutes before the start of chemotherapy.¹ If administered 30 minutes before chemotherapy, providers may bill CPT Code 96375, indicating POSFREA™ as an additional, sequential push of a new substance or drug.

ICD Diagnosis Codes^{6,7}

For drugs with multiple indications, it is best practice to code the most specific ICD-10-CM Code within the indication to justify medical necessity.

International Classification of Disease, 10th Edition, Clinical Modification Codes for POSFREA™	
Indication	ICD-10-CM Codes
Adverse Effect – Anesthetics	T41.0X5A, T41.1X5A, T41.205A, T41.295A, T41.45XA, T88.59XA
Adverse Effect – Antineoplastic and Immunosuppressive Drugs	T41.1X5A, T41.1X5D, T41.1X5S
Encounter for Antineoplastic Chemotherapy	Z51.11
Encounter for Antineoplastic Immunotherapy	Z51.12
Vomiting and Nausea	R11.0, R11.10, R11.11, R11.12, R11.2

ICD Diagnosis Codes by Indication

ICD-10-CM coding for POSFREA™ varies greatly by payer. Please check with each payer to ascertain the best coding for POSFREA™ according to their policy.

Adverse Effect – Anesthetics: ICD-10-CM Diagnosis Coding	
ICD-10 Code	Descriptor
T41.0X5A	Adverse effect of inhaled anesthetics, initial encounter
T41.1X5A	Adverse effect of intravenous anesthetics, initial encounter
T41.205A	Adverse effect of unspecified general anesthetics, initial encounter
T41.295A	Adverse effect of other general anesthetics, initial encounter
T41.45XA	Adverse effect of unspecified anesthetic, initial encounter
T88.59XA	Other complications of anesthesia, initial encounter

Adverse Effect – Antineoplastic and Immunosuppressive Drugs: ICD-10-CM Diagnosis Coding	
ICD-10 Code	Descriptor
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5D	Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs, sequela

Encounter for Chemotherapy: ICD-10-CM Diagnosis Coding	
ICD-10 Code	Descriptor
Z51.11	Encounter for antineoplastic chemotherapy
Encounter for Immunotherapy: ICD-10-CM Diagnosis Coding	
ICD-10 Code	Descriptor
Z51.12	Encounter for antineoplastic immunotherapy

Vomiting and Nausea: ICD-10-CM Diagnosis Coding	
ICD-10 Code	Descriptor
R11.0	Nausea
R11.10	Vomiting, unspecified
R11.11	Vomiting without nausea
R11.12	Projectile vomiting
R11.2	Nausea with vomiting, unspecified

Please see Important Safety Information on pages 3 and 13 and full [Prescribing Information](#) for POSFREA.™

SAMPLE UB-04 / CMS 1450 Claim Form

Form Locator (FL) 42

(Electronic Claim Form = Loop 2400, Segment Type SV201):

List the appropriate revenue code for the drug. Match the descriptor for POSFREA™ Injection to your revenue code, 0260.

Additionally, enter an appropriate revenue code for the administration service, 0335 for chemotherapy, or others based on the cost center in which the service was performed.

FL 43

(NOT REQUIRED BY MEDICARE):

Enter the description of the procedure for the Revenue Code billed. If required, the N4 indicator first, then the 11-digit NDC code. In the third space, list the unit measurement code, and last, the quantity. Check with other payers for their requirements.

FL 44

(Electronic Claim Form = Loop 2400, SV202-1=HC/HP):

Enter the appropriate HCPCS code - **J2468: Injection, palonosetron hydrochloride (AVYXA™), not therapeutically equivalent to J2469, 25 micrograms**

POSFREA™ Injection is packaged as a single-dose vial. Medicare requires drug waste be reported with the -JW modifier on a separate line. If there is no waste, POSFREA™ Injection must be billed on one line with modifier -JZ. Medicare requires this; please ascertain if other payers require JZ and JW modifiers.

For administration, enter the appropriate code or codes for the infusion duration. As an example, a 30 second infusion of POSFREA™ Injection requires code CPT Code 96374.

FL 42

FL 44

1		2		3a PAY CNTL #		4 TOP OF BILL	
5 MED REC #		5 FED. TAX NO.		6 STATEMENT COVERS PERIOD FROM		7 THROUGH	
8 PATIENT NAME				9 PATIENT ADDRESS			
10 BIRTHDATE		11 SEX		12 DATE		13 ADMISSION	
14 TYPE		15 SRC		16 CHR		17 STAT	
18		19		20		21	
22		23		24		25	
26		27		28		29	
30		31		32		33	
34		35		36		37	
38		39		40		41	
42		43		44		45	
46		47		48		49	
50		51		52		53	
54		55		56		57	
58		59		60		61	
62		63		64		65	
66		67		68		69	
70		71		72		73	
74		75		76		77	
78		79		80		81	
82		83		84		85	
86		87		88		89	
90		91		92		93	
94		95		96		97	
98		99		100		101	
102		103		104		105	
106		107		108		109	
110		111		112		113	
114		115		116		117	
118		119		120		121	
122		123		124		125	
126		127		128		129	
130		131		132		133	
134		135		136		137	
138		139		140		141	
142		143		144		145	
146		147		148		149	
150		151		152		153	
154		155		156		157	
158		159		160		161	
162		163		164		165	
166		167		168		169	
170		171		172		173	
174		175		176		177	
178		179		180		181	
182		183		184		185	
186		187		188		189	
190		191		192		193	
194		195		196		197	
198		199		200		201	
202		203		204		205	
206		207		208		209	
210		211		212		213	
214		215		216		217	
218		219		220		221	
222		223		224		225	
226		227		228		229	
230		231		232		233	
234		235		236		237	
238		239		240		241	
242		243		244		245	
246		247		248		249	
250		251		252		253	
254		255		256		257	
258		259		260		261	
262		263		264		265	
266		267		268		269	
270		271		272		273	
274		275		276		277	
278		279		280		281	
282		283		284		285	
286		287		288		289	
290		291		292		293	
294		295		296		297	
298		299		300		301	
302		303		304		305	
306		307		308		309	
310		311		312		313	
314		315		316		317	
318		319		320		321	
322		323		324		325	
326		327		328		329	
330		331		332		333	
334		335		336		337	
338		339		340		341	
342		343		344		345	
346		347		348		349	
350		351		352		353	
354		355		356		357	
358		359		360		361	
362		363		364		365	
366		367		368		369	
370		371		372		373	
374		375		376		377	
378		379		380		381	
382		383		384		385	
386		387		388		389	
390		391		392		393	
394		395		396		397	
398		399		400		401	
402		403		404		405	
406		407		408		409	
410		411		412		413	
414		415		416		417	
418		419		420		421	
422		423		424		425	
426		427		428		429	
430		431		432		433	
434		435		436		437	
438		439		440		441	
442		443		444		445	
446		447		448		449	
450		451		452		453	
454		455		456		457	
458		459		460		461	
462		463		464		465	
466		467		468		469	
470		471		472		473	
474		475		476		477	
478		479		480		481	
482		483		484		485	
486		487		488		489	
490		491		492		493	
494		495		496		497	
498		499		500		501	
502		503		504		505	
506		507		508		509	
510		511		512		513	
514		515		516		517	
518		519		520		521	
522		523		524		525	
526		527		528		529	
530		531		532		533	
534		535		536		537	
538		539		540		541	
542		543		544		545	
546		547		548		549	
550		551		552		553	
554		555		556		557	
558		559		560		561	
562		563		564		565	
566		567		568		569	
570		571		572		573	
574		575		576		577	
578		579		580		581	
582		583		584		585	
586		587		588		589	
590		591		592		593	
594		595		596		597	
598		599		600		601	
602		603		604		605	
606		607		608		609	
610		611		612		613	
614		615		616		617	
618		619		620		621	
622		623		624		625	
626		627		628		629	
630		631		632		633	
634		635		636		637	
638		639		640		641	
642		643		644		645	
646		647		648		649	
650		651		652		653	
654		655		656		657	
658		659		660		661	
662		663		664		665	
666		667		668		669	
670		671		672		673	
674		675		676		677	
678		679		680		681	
682		683		684		685	
686		687		688		689	
690		691		692		693	
694		695		696		697	
698		699		700		701	
702		703		704		705	
706		707		708		709	
710		711		712		713	
714		715		716		717	
718		719		720		721	
722		723		724		725	
726		727		728		729	
730		731		732		733	
734		735		736		737	
738		739		740		741	
742		743		744		745	
746		747		748		749	
750		751		752		753	
754		755		756		757	
758		759		760		761	
762		763		764		765	
766		767		768		769	
770		771		772		773	
774		775		776		777	
778		779		780		781	
782		783		784		785	
786		787		788		789	
790		791		792		793	
794		795		796		797	
798		799		800		801	
802		803		804		805	
806		807		808		809	
810		811		812		813	
814		815		816		817	
818		819		820		821	
822		823		824		825	
826		827		828		829	
830		831		832		833	
834							

FL 45

(Electronic Claim Form = Loop 2400, Segment DTP/472/03):

Enter the date of service

FL 46

(Electronic Claim Form Loop 2400, SV205):

Enter the units for the HCPCS code billed. Enter the number of service units for each item. For example, 10 units if using one .25 mg/5 mL single-dose vial of POSFREA™ Injection

FL 63

(Electronic Claim Form= Loop 2300, REF/G1/02):

Enter treatment authorization code.

FL 67A-Q

(Electronic Claim Form = Loop 2300, HI01-2 (HI01-1=BK):

Enter a diagnosis code for the drug documented in the medical record. Be as specific as possible. The code listed here is an example for POSFREA™ Injection: Z51.11, Encounter for antineoplastic chemotherapy

FL 63**FL 67A-Q**

1		2		3a PAT CONTL #		3b MED REC #		4	
5		6		7		8		9	
10 BIRTHDATE		11 SEX		12 DATE		13 HR		14 TYPE	
15 SRC		16 DHR		17 STAT		18		19	
20		21		22		23		24	
25		26		27		28		29	
30		31		32		33		34	
35		36		37		38		39	
40		41		42		43		44	
45		46		47		48		49	
50		51		52		53		54	
55		56		57		58		59	
60		61		62		63		64	
65		66		67		68		69	
70		71		72		73		74	
75		76		77		78		79	
80		81		82		83		84	
85		86		87		88		89	
90		91		92		93		94	
95		96		97		98		99	
100		101		102		103		104	
105		106		107		108		109	
110		111		112		113		114	
115		116		117		118		119	
120		121		122		123		124	
125		126		127		128		129	
130		131		132		133		134	
135		136		137		138		139	
140		141		142		143		144	
145		146		147		148		149	
150		151		152		153		154	
155		156		157		158		159	
160		161		162		163		164	
165		166		167		168		169	
170		171		172		173		174	
175		176		177		178		179	
180		181		182		183		184	
185		186		187		188		189	
190		191		192		193		194	
195		196		197		198		199	
200		201		202		203		204	
205		206		207		208		209	
210		211		212		213		214	
215		216		217		218		219	
220		221		222		223		224	
225		226		227		228		229	
230		231		232		233		234	
235		236		237		238		239	
240		241		242		243		244	
245		246		247		248		249	
250		251		252		253		254	
255		256		257		258		259	
260		261		262		263		264	
265		266		267		268		269	
270		271		272		273		274	
275		276		277		278		279	
280		281		282		283		284	
285		286		287		288		289	
290		291		292		293		294	
295		296		297		298		299	
300		301		302		303		304	
305		306		307		308		309	
310		311		312		313		314	
315		316		317		318		319	
320		321		322		323		324	
325		326		327		328		329	
330		331		332		333		334	
335		336		337		338		339	
340		341		342		343		344	
345		346		347		348		349	
350		351		352		353		354	
355		356		357		358		359	
360		361		362		363		364	
365		366		367		368		369	
370		371		372		373		374	
375		376		377		378		379	
380		381		382		383		384	
385		386		387		388		389	
390		391		392		393		394	
395		396		397		398		399	
400		401		402		403		404	
405		406		407		408		409	
410		411		412		413		414	
415		416		417		418		419	
420		421		422		423		424	
425		426		427		428		429	
430		431		432		433		434	
435		436		437		438		439	
440		441		442		443		444	
445		446		447		448		449	
450		451		452		453		454	
455		456		457		458		459	
460		461		462		463		464	
465		466		467		468		469	
470		471		472		473		474	
475		476		477		478		479	
480		481		482		483		484	
485		486		487		488		489	
490		491		492		493		494	
495		496		497		498		499	
500		501		502		503		504	
505		506		507		508		509	
510		511		512		513		514	
515		516		517		518		519	
520		521		522		523		524	
525		526		527		528		529	
530		531		532		533		534	
535		536		537		538		539	
540		541		542		543		544	
545		546		547		548		549	
550		551		552		553		554	
555		556		557		558		559	
560		561		562		563		564	
565		566		567		568		569	
570		571		572		573		574	
575		576		577		578		579	
580		581		582		583		584	
585		586		587		588		589	
590		591		592		593		594	
595		596		597		598		599	
600		601		602		603		604	
605		606		607		608		609	
610		611		612		613		614	
615		616		617		618		619	
620		621		622		623		624	
625		626		627		628		629	
630		631		632		633		634	
635		636		637		638		639	
640		641		642		643		644	
645		646		647		648		649	
650		651		652		653		654	
655		656		657		658		659	
660		661		662		663		664	
665		666		667		668		669	
670		671		672		673		674	
675		676		677		678		679	
680		681		682		683		684	
685		686		687		688		689	
690		691		692		693		694	
695		696		697		698		699	
700		701		702		703		704	
705		706		707		708		709	
710		711		712		713		714	
715		716		717		718		719	
720		721		722		723		724	
725		726		727		728		729	
730		731		732		733		734	
735		736		737		738		739	
740		741		742		743		744	
745		746		747		748		749	
750		751		752		753		754	
755		756		757		758		759	
760		761		762		763		764	
765		766		767		768		769	
770		771		772		773		774	
775		776		777		778		779	
780		781		782		783		784	
785		786		787		788		789	
790		791		792		793		794	
795		796		797		798		799	
800		801		802		803		804	
805		806		807		808		809	
810		811		812		813		814	
815		816		817		818		819	
820		821		822		823		824	
825		826		827		828		829	
830		831		832		833		834	
835		836		837		838		839	
840		841		842		843		844	
845		846		847		848		849	
850		851		852		853		854	
855		856		857		858		859	
860		861		862		863		864	
865		866		867		868		869	
870		871		872		873		874	

SAMPLE CMS 1500 Claim Form

Box 21

(Electronic Claim Form = Loop 2300, Segment H101-2 through H112=2):

Enter the patient's diagnosis from the patient's medical record. An example code for POSFREA™ injection is **Z51.11 - Encounter for Antineoplastic Chemotherapy**

Use Box 21 B-L fields for secondary diagnoses.

Box 23

(Electronic Claim Form = Loop 2300, REF02):

Enter prior authorization number if one exists.

Box 24D

(Electronic Claim Form = Loop 2400, Segment SV101):

Enter the appropriate HCPCS code - **J2468: Injection, palonosetron hydrochloride (AVYXA™), not therapeutically equivalent to J2469, 25 micrograms**

POSFREA™ Injection is packaged as a single-dose vial. Medicare requires drug waste be reported with the -JW modifier on a separate line. If there is no waste, POSFREA™ Injection must be billed on one line with modifier -JZ. Medicare requires this; please ascertain if other payers require JZ and JW modifiers.

For administration, enter the appropriate code or codes for the infusion duration. As an example, CPT code 96375 indicates a therapeutic, prophylactic, or diagnostic injection. List this code separately to primary procedure, 96413, chemotherapy administration.

Box 24E

(Electronic Claim Form = Loop 2400, Segment SV107):

Specify the diagnosis letter that corresponds with the drug and drug administration code(s) in Box 21.



HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE ☐ MEDICAID ☐ TRICARE ☐ CHAMPVA ☐ GROUP HEALTH PLAN ☐ FECA BLU (LUNG) ☐ OTHER ☐		1a. INSURED'S I.D. NUMBER (For Program in Item 1)	
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)		4. INSURED'S NAME (Last Name, First Name, Middle Initial)	
3. PATIENT'S BIRTH DATE MM DD YY SEX M ☐ F ☐		7. INSURED'S ADDRESS (No., Street)	
5. PATIENT'S ADDRESS (No., Street)		6. PATIENT RELATIONSHIP TO INSURED Self ☐ Spouse ☐ Child ☐ Other ☐	
CITY STATE		CITY STATE	
ZIP CODE TELEPHONE (Include Area Code)		ZIP CODE TELEPHONE (Include Area Code)	
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)		10. IS PATIENT'S CONDITION RELATED TO:	
a. OTHER INSURED'S POLICY OR GROUP NUMBER		a. EMPLOYMENT? (Current or Previous) YES ☐ NO ☐	
b. RESERVED FOR NUCC USE		b. AUTO ACCIDENT? YES ☐ NO ☐ PLACE (State) _____	
c. RESERVED FOR NUCC USE		c. OTHER ACCIDENT? YES ☐ NO ☐	
d. INSURANCE PLAN NAME OR PROGRAM NAME		10d. CLAIM CODES (Designated by NUCC)	
11. INSURED'S POLICY GROUP OR FECA NUMBER			
a. INSURED'S DATE OF BIRTH MM DD YY SEX M ☐ F ☐			
b. OTHER CLAIM ID (Designated by NUCC)			
c. INSURANCE PLAN NAME OR PROGRAM NAME			
d. IS THERE ANOTHER HEALTH BENEFIT PLAN? YES ☐ NO ☐ If yes, complete items 9, 9a, and 9d.			
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE (I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.)			
13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE (I authorize payment of medical benefits to the undersigned physician or supplier for services described below.)			
14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP) MM DD YY QUAL		15. OTHER DATE MM DD YY	
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE		17a. ICD-9-CM 17b. NPI	
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)			
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate A-L to service line below (24E))			
A. _____ B. _____ C. _____ D. _____			
E. _____ F. _____ G. _____ H. _____			
I. _____ J. _____ K. _____ L. _____			
24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY		D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) OPT/HCPCS MODIFIER	
25. FEDERAL TAX I.D. NUMBER SSN EIN		27. ACCEPT ASSIGNMENT? (For govt claims, see back) YES ☐ NO ☐	
26. PATIENT'S ACCOUNT NO.		28. TOTAL CHARGE \$	
29. AMOUNT PAID \$		30. Paid for NUCC Use	
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREE(S) OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)			
32. SERVICE FACILITY LOCATION INFORMATION			
33. BILLING PROVIDER INFO & PH # ()			
SIGNED DATE		SIGNED DATE	

Box 21

Box 24D

Box 24E

Box 23

Box 24G

(Electronic Claim Form = Loop 2400, SV104):

Enter the number of service units for each item.

Box 24A-B

(Electronic Claim Form: Box 24A (Electronic Claims = Loop 2400, DTP02; Box 24 B (Loop 2300/2400, Segment CLM05-1/ SV105)

In the non-shaded area, enter the appropriate date of service and place of service code. Example: Office = 11

In the shaded area, enter the N4 indicator first, then the 11-digit NDC code. In the third space, list the unit measurement code, and last, the quantity.

An example for this drug is N4838310105015ML

Box 24A-B**HEALTH INSURANCE CLAIM FORM**

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE MEDICAID TRICARE CHAMPVA GROUP HEALTH PLAN FECA BOX (LUNG) OTHER ☐ (Medicare#) ☐ (Medical#) ☐ (ID#(DOD#)) ☐ (Member ID#) ☐ (ID#) ☐ (ID#) ☐ (ID#)										1a. INSURED'S I.D. NUMBER (For Program in Item 1)																			
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)										3. PATIENT'S BIRTH DATE MM DD YY SEX M ☐ F ☐										4. INSURED'S NAME (Last Name, First Name, Middle Initial)									
5. PATIENT'S ADDRESS (No., Street)										6. PATIENT RELATIONSHIP TO INSURED Self ☐ Spouse ☐ Child ☐ Other ☐										7. INSURED'S ADDRESS (No., Street)									
CITY STATE										CITY STATE																			
ZIP CODE TELEPHONE (Include Area Code)										ZIP CODE TELEPHONE (Include Area Code)																			
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)										10. IS PATIENT'S CONDITION RELATED TO:										11. INSURED'S POLICY GROUP OR FECA NUMBER									
a. OTHER INSURED'S POLICY OR GROUP NUMBER										a. EMPLOYMENT? (Current or Previous) YES ☐ NO ☐										a. INSURED'S DATE OF BIRTH MM DD YY SEX M ☐ F ☐									
b. RESERVED FOR NUCC USE										b. AUTO ACCIDENT? YES ☐ NO ☐ PLACE (State)										b. OTHER CLAIM ID (Designated by NUCC)									
c. RESERVED FOR NUCC USE										c. OTHER ACCIDENT? YES ☐ NO ☐										c. INSURANCE PLAN NAME OR PROGRAM NAME									
d. INSURANCE PLAN NAME OR PROGRAM NAME										10d. CLAIM CODES (Designated by NUCC)										d. IS THERE ANOTHER HEALTH BENEFIT PLAN? YES ☐ NO ☐ If yes, complete items 9, 9a, and 9d.									
READ BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM.																													
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.															13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.														
SIGNED DATE															SIGNED														
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY QUAL															15. OTHER DATE MM DD YY QUAL														
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE															17a. 17b. NPI														
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)																													
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24b) ICD Ind.																													
A. B. C. D. E. F. G. H. I. J.																													
24. A. DATE(S) OF SERVICE From To B. PLACE OF SERVICE C. D. PROCEDURES, SERVICES, OR SUPPLIES (E-plain Unusual Circumstances) EPT/HCPCS MODIFIER E. DIAGNOSIS POINTER F. G. DAYS OF SERVICE H. I. ID. QUAL J. RENDERING PROVIDER ID. #																													
1															Box 24G NPI														
2															NPI														
3															NPI														
4															NPI														
5															NPI														
6															NPI														
25. FEDERAL TAX I.D. NUMBER SSN EIN															26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? (or pre-claim, per 24b) YES ☐ NO ☐														
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)															32. SERVICE FACILITY LOCATION INFORMATION														
SIGNED DATE															33. BILLING PROVIDER INFO & PH # ()														
a. NPI b.															a. NPI b.														

NUCC Instruction Manual available at: www.nucc.org

PLEASE PRINT OR TYPE

APPROVED CMS-0338-1197 FORM 1500 (02-12)

[1] CPT Code 96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug/initial infusion times may vary. **Electronic Claim Reference:** Noridian Healthcare (n.d.). CMS-1500 Claim Form Crosswalk to EMC Loops and Segments. Noridian Healthcare Solutions. Retrieved April 5, 2023, from <https://med.noridianmedicare.com/web/jeb/topics/claim-submission/cms-1500-crosswalk-emc-loops-segments>

CPT Codes are a registered trademark of the American Medical Association (AMA), All Rights Reserved
 THIS INFORMATION IS PROVIDED FOR EDUCATIONAL PURPOSES ONLY AND IS NOT A GUARANTEE OF COVERAGE. IT IS THE SOLE RESPONSIBILITY OF THE HEALTH CARE PROVIDER TO SELECT THE PROPER CODES AND ENSURE THE ACCURACY OF ALL STATEMENTS USED IN SEEKING COVERAGE AND REIMBURSEMENT FOR AN INDIVIDUAL PATIENT.

IMPORTANT SAFETY INFORMATION (CONTINUED)

If symptoms of serotonin syndrome occur, discontinue POSFREA and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if POSFREA is used concomitantly with other serotonergic drugs.

ADVERSE REACTIONS

Most common adverse reactions in

- chemotherapy-induced nausea and vomiting in adults ($\geq 5\%$) are: headache and constipation.
- postoperative nausea and vomiting ($\geq 2\%$) are: QT prolongation, bradycardia, headache, and constipation.

DRUG INTERACTIONS

Serotonergic Drugs: Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT₃ receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Monitor for the emergence of serotonin syndrome. If symptoms occur, discontinue POSFREA and initiate supportive treatment.

USE IN SPECIFIC POPULATIONS

Pediatric Use:

Chemotherapy-Induced Nausea and Vomiting (CINV): Safety and effectiveness of POSFREA have been established in pediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including HEC.

Postoperative Nausea and Vomiting (PONV): Safety and effectiveness have not been established in pediatric patients for PONV.

OVERDOSAGE

There is no known antidote to palonosetron. Overdose should be managed with supportive care.

Please see the full [Prescribing Information](#) for safety information, and dosing guidelines.

To report SUSPECTED ADVERSE REACTIONS, contact Avyxa Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Notes

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

References:

1. POSFREA™ Full Prescribing Information. Parsippany, NJ. AVYXA™ Pharma. Revised April 2025.
2. CMS. Healthcare Common Procedure Coding System Level II Coding Procedures 2023. Accessed August 19, 2024. <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system>
3. CMS. Billing and Coding: Approved Drugs and Pharmaceuticals; Includes Cancer Chemotherapeutic Agents. Revised November 2, 2023. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=53049&ver=98>
4. Current Procedural Terminology. 2024 ® American Medical Association
5. CMS. Billing and Coding: JW and JZ Modifier Billing Guidelines. Article ID A55932. Revised March 21, 2024. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55932>.
6. CDC. Classification of Diseases, Functioning, and Disability. Revised June 7, 2024 <https://www.cdc.gov/nchs/icd/>
7. CDC. National Center for Health Statistics. ICD-10-CM Fiscal Year Releases. Revised April 1, 2024. <https://www.cdc.gov/nchs/icd/icd-10-cm/files.html>

